To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

The primary purpose of the study is to assess the effect of hepatic impairment on the PK of tavapadon following administration of a single oral dose in participants with mild and moderate hepatic impairment relative to age, body weight, and sex-matched participants with normal hepatic function.

Key facts

Study ID

NCT05404529

Run by

Cerevel Therapeutics, LLC

People needed

32

Starts

2022-04-29

Expected to finish

2023-01-24

Last updated by the study team

2023-05-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• Miami, Florida — Miami, Florida, United States
• Orlando, Florida — Orlando, Florida, United States
• San Antonio, Texas — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.